FDA Issues Tentative Approval to Lu 177 Dotatate Radioequivalent for GEP-NETs

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs.¹

The ANDA for the radioequivalent was accepted for filing by the FDA in January 2024.² The tentative approval signifies that the drug meets all required quality, safety, and efficacy standards for domestic marketing but is subject to existing patent protections or exclusivity periods for the reference listed drug (RLD). According to developer Lantheus, final FDA approval and subsequent commercial availability are anticipated following the expiration of the RLD’s exclusivity period in June 2026.

“As the first radioequivalent [of Lu 177 dotatate] to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP-NETs. This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies,” said Mary Anne Heino, CEO of Lantheus, in a news release.¹ “We remain committed to meeting this growing demand and look forward to making PNT2003 available to patients pending final FDA approval.”

Lutetium Lu 177 dotatate is a peptide receptor radionuclide therapy (PRRT) that consists of a radionuclide conjugated to a somatostatin analog. The compound exhibits high affinity for SSTR2, which is frequently overexpressed on the surface of GEP-NET cells. Upon binding, the complex is internalized, delivering localized beta-minus radiation that induces DNA damage and subsequent cellular apoptosis.

The tentative approval of PNT2003 is predicated on demonstrated radioequivalence to the RLD. This decision suggests that the pharmacokinetic profile and radiation dosimetry of the generic lutetium Lu 177 dotatate are comparable with the established standard of care. The introduction of a radioequivalent product is expected to expand the supply chain for radiopharmaceuticals, which have historically faced logistical and manufacturing constraints.

Clinical Context: NETTER-1 Trial

The clinical utility of lutetium Lu 177 dotatate was originally established by the landmark phase 3 NETTER-1 trial (NCT01578239), a randomized, multicenter study that evaluated the PRRT plus best supportive care with octreotide long-acting release (Sandostatin LAR) against high-dose octreotide LAR alone in 231 patients with progressive, SSTR+ midgut NETs.³

In the primary analysis, patients treated with the radioligand therapy experienced a notable reduction in the risk of disease progression or death compared with those receiving high-dose octreotide long-acting release.⁴ The estimated progression-free survival (PFS) at 20 months was 65.2% in the experimental group vs 10.8% in the control group. Additionally, response rates were significantly higher in the experimental group than in the control group (18% vs 3%; P <.001).

In the final analysis, including an analysis of the trial’s secondary end point of overall survival (OS), treatment with lutetium Lu 177 dotatate did not significantly improve median OS vs the control treatment.⁵ However, the 11.7-month numeric improvement in median OS with the therapy may be considered clinically meaningful.

In terms of safety, the safety profile of lutetium Lu 177 dotatate is well-characterized, with common adverse events including nausea, vomiting, fatigue, and myelosuppression.

REFERENCES

1. Lantheus receives FDA tentative approval for lutetium Lu 177 dotatate (PNT2003), radioequivalent to Lutathera®. News release. Lantheus. March 2, 2026. Accessed March 3, 2026. https://tinyurl.com/mw8dw2pe

2. Lantheus announces acceptance of its first-to-file ANDA for generic LUTATHERA (lutetium Lu 177 dotatate). News release. Lantheus. January 11, 2024. Accessed March 3, 2026. https://tinyurl.com/mt6ft9yw

3. A study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor–positive midgut carcinoid tumours (NETTER-1). ClinicalTrials.gov. Updated April 4, 2022. Accessed March 3, 2026. https://clinicaltrials.gov/study/NCT01578239

4. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427

5. Strosberg JR, Caplin ME, Kunz PL, et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6